Bristol

Bristol Myers Squibb is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company maintains a dominant presence in oncology, hematology, immunology, and cardiovascular health through a portfolio of blockbuster therapies such as Opdivo and Eliquis. Following major acquisitions of Celgene, MyoKardia, and Karuna Therapeutics, BMS has significantly expanded its capabilities in cell therapy, precision medicine, and neuroscience. Its research and development strategy focuses on high-value targets and diverse modalities to address significant unmet medical needs. The company operates a global manufacturing and commercial infrastructure to support its extensive pipeline and marketed products.